What technical signals does Wonbiogen (307280) have?

Wonbiogen current technical signals: no active technical signal.

Is Wonbiogen a cup-and-handle pattern?

No. Wonbiogen has no valid cup-and-handle signal right now.

What are Wonbiogen's financials and valuation?

Wonbiogen's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Wonbiogen

307280 · KOSDAQ

₩6,070-1.62%

2026-09-04 close

Wonbiogen last closed at ₩6,070 (-1.62%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…

No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions

303 picks

Next-day win rate

50.7%

Avg next-day

-0.11%

vs market

-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Signal history

Date	Signal	+20 trading days

A record, not a prediction.

How this is calculated

"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Trade plan

EntryAccount sizeStopTarget (optional)Risk per trade (%)

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

A+

Overall: 건강관리 6/291 · top 2%

Factor composite · relative position in sector

PER 7.57 · PBR 1.16 — own-history percentile 89/100 · 76/100

Open self-history band

PER89/100

PBR76/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend (per share · split-adjusted) · as of 2025

Consistency

Yield

C+

Safety

C+

Reference indicatorView observed cut rates

Paid 3 consecutive years · Raised 0 consecutive years · Yield 1.65% (based on 2025 payment of 100원)

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024

Safe zoneFinancial-metric reference signal

Altman Z'' zoneZ'' 15.92

Distress

Grey

Safe

The marker shows the current Z'' value within the displayed zones.

Altman Z'': 15.92
Beneish M-Score: -2.73
Sloan accrual: -7.66%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

8/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score8/9

Profitability

Positive ROAPass
Positive OCFPass
Improving ΔROAPass
Accruals (OCF > net income)Pass

Leverage & liquidity

Lower debtPass
Higher current ratioPass
No new sharesPass

Efficiency

Higher gross marginNot passed
Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 189 of 287, share 0%.

189 / 2870%revenue share

Who dominates this industry?

1삼성바이오로직스7.3%
2셀트리온5.7%
3녹십자홀딩스3.5%
4유한양행3.3%
5대웅3.1%
6원바이오젠0%

Concentration

DistributedCR3 16.6%

HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p: 31.61
Direction: 확대
Level: 넓음
Years: 7

Value lens

P90/P10: 13.9
Median P/B: 1.47
Level: 넓음
n: 263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin: 20.4%
Interest coverage: 107.5x
Return on equity (ROE): 15.3%

Operating margin −5pp

Tolerable

Interest coverageBase 107.5x81.2x

Return on equity (ROE)Base 15.3%12.4%

Revenue −15%

Tolerable

Interest coverageBase 107.5x91.4x

Return on equity (ROE)Base 15.3%14%

Interest rate +2pp

Tolerable

Interest coverageBase 107.5x44.7x

Return on equity (ROE)Base 15.3%16.3%

Interest coverage limit

Current margin 20.2pp

Interest coverage limit at an operating margin of 0.2%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-23

Suppliers disclosed by the company in its 2026-03-23 annual report.

Suppliers without disclosed amount

USD

Connections

AI-extracted related companies · for reference

Competitors

메디톡스Price comovement r=0.27 (1 year)휴젤Price comovement r=0.23 (1 year)대웅제약Price comovement r=0.35 (1 year)LG화학Price comovement r=0.26 (1 year)한미약품Price comovement r=0.13 (1 year)GC녹십자셀트리온Price comovement r=0.32 (1 year)존슨앤드존슨 애브비 앨러간 에스테틱스

Same theme

메디컬에스테틱보툴리눔 톡신필러피부미용 의료기기

🔗 See in the full market map →

Recent filings

Wonbiogen's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About Wonbiogen

What technical signals does Wonbiogen (307280) have?: Wonbiogen current technical signals: no active technical signal.
Is Wonbiogen a cup-and-handle pattern?: No. Wonbiogen has no valid cup-and-handle signal right now.
What are Wonbiogen's financials and valuation?: Wonbiogen's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy